Scandinavian ChemoTech AB (publ) (STO:CMOTEC.B)

Market Cap	38.98M
Revenue (ttm)	7.69M
Net Income (ttm)	-13.84M
Shares Out	23.34M
EPS (ttm)	-0.63
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	30,693
Average Volume	34,614
Open	1.455
Previous Close	1.515
Day's Range	1.455 - 1.680
52-Week Range	0.880 - 3.000
Beta	1.45
RSI	42.22
Earnings Date	Aug 12, 2025

About Scandinavian ChemoTech AB

Scandinavian ChemoTech AB (publ) offers cancer care and pain management solutions in Sweden. The company offers IQWave, an electroporation device, used for electrochemotherapy and treatment of head and neck cancer, squamous cell carcinoma, malignant melanoma, basal cell carcinoma, adenocarcinoma of the breast and salivary gland, hypernephroma, kaposi sarcoma, and transitional cell carcinoma. It also offers Vetiqure for the treatment of superficial tumors in dogs, cats, and horses. The company markets its products through distribution channels a...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 6
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: CMOTEC.B

Financial Performance

In 2024, Scandinavian ChemoTech AB's revenue was 6.57 million, an increase of 132.67% compared to the previous year's 2.82 million. Losses were -13.72 million, -34.96% less than in 2023.